Clinical Trial in Chinese Healthy Volunteers of GB222
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and similarities and safety of other pharmacokinetic (PK) parameters (Cmax, AUC0-∞ etc.) and immunogenicity of GB222 and bevacizumab after single administration.
Non-small Cell Lung Cancer
BIOLOGICAL: GB222|BIOLOGICAL: Bevacizumab
AUC 0- t, AUC 0- t, Up to 84 days
Cmax, Cmax, Up to 84 days|AUC0-∞, AUC0-∞, Up to 84 days|ADA, ADA, Up to 84 days
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and similarities and safety of other pharmacokinetic (PK) parameters (Cmax, AUC0-∞ etc.) and immunogenicity of GB222 and bevacizumab after single administration.